Neuraxis Inc (NRXS)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Neuraxis Inc Stock (NRXS) Company Profile

Neuraxis Inc

Healthcare (1176)

Biotechnology (685)

(812) 689-0791

11550 North Meridian Street, Suite 325, Carmel

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NRXS's Discussions on Twitter

Vergleichen Sie NRXS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NRXS Neuraxis Inc	2.84	19.82M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Neuraxis Inc Aktie (NRXS) Neueste Nachrichten

Finanzdaten der Neuraxis Inc-Aktie (NRXS)

Es liegen keine Finanzdaten für Neuraxis Inc (NRXS) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Neuraxis Inc (NRXS)

Neuraxis Inc Stock (NRXS) Company Profile

Vergleichen Sie NRXS mit anderen Aktien

Neuraxis Inc Aktie (NRXS) Neueste Nachrichten

NeurAxis, Inc. Announces New Medical Policy Coverage with a Prominent Insurer for over Five Million Lives Across Multiple States - Marketscreener.com

UPDATENeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States - The Manila Times

NeurAxis Expands IBS Treatment Coverage to 51M Lives, Targets Youth Market with Novel Device - StockTitan

NeurAxis Announces New Medical Policy Coverage with Molina - GlobeNewswire

NeurAxis Expands Coverage for FDA-Cleared IBS Pain Device to 51M Lives with Molina Deal - StockTitan

NeurAxis announces Q4 preliminary unaudited revenues were about $800 thousand - MSN

Vagus Nerve Stimulators Market Growth in Future Scope 2025-2032 - openPR

Critical Analysis: Precision Optics (NASDAQ:POCI) & NeurAxis (NASDAQ:NRXS) - Defense World

Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors - The Manila Times

NeurAxis Inc. Issues Letter to Shareholders - GlobeNewswire

NeurAxis IB-Stim Reaches Major Milestone: Insurance Coverage Surges to 51 Million Lives, FDA Expands Age Range - StockTitan

NeurAxis, Inc. Reports Strong Preliminary Unaudited Fourth Quarter 2024 Results - Defense World

Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World

NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year - Marketscreener.com

Everything Blockchain Inc. Announces Letter to Shareholders from CEO - The Manila Times

NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth - GlobeNewswire

NeurAxis Q4 Revenue Surges 50% as IB-Stim Coverage Reaches 45 Million Lives - StockTitan

NeurAxis (NASDAQ:NRXS) Shares Down 4.1% – What’s Next? - Defense World

Model N Appoints New Chief Executive Officer, Bret Connor - The Manila Times

NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - GlobeNewswire

NeurAxis CEO to Present at Lytham Partners 2025 Healthcare Investor Summit - StockTitan

MicroCap Opportunities 2024 Year-End Portfolio Update - substack.com

FDA Approvals News Live Feed - StockTitan

Vagus Nerve Stimulators Market Growth in Future Scope 2024-2031 - openPR

NeurAxis (NASDAQ:NRXS) Stock Price Down 5.3% – Here’s What Happened - Defense World

NeurAxis Inc. Announces FDA 510(k) Clearance of Red for Testing and Evaluation of Patients with Chronic Constipation - Marketscreener.com

Connyct Launches on iOS: Build Your College Crew, Share Your Vibe, and Never Miss a Party - The Manila Times

NeurAxis Inc. Announces FDA 510(k) Clearance of RED for - GlobeNewswire

NeurAxis Secures FDA Clearance for Revolutionary Chronic Constipation Testing Device - StockTitan

FDA Awards New Clearance to NeurAxis’ IB-Stim - MPO-mag

Rosalind Advisors, Inc. Acquires Significant Stake in Neuraxis I - GuruFocus.com

Neuraxis increases Series B Preferred Stock and extends dividend rights By Investing.com - Investing.com South Africa

Neuraxis increases Series B Preferred Stock and extends dividend rights - Investing.com

NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage - MSN

Critical Review: BioSig Technologies (NASDAQ:BSGM) vs. NeurAxis (NASDAQ:NRXS) - Defense World

NeurAxis, Inc. (NASDAQ:NRXS) Q3 2024 Earnings Call Transcript - MSN

Neuraxis secures $5 million in preferred stock sale By Investing.com - Investing.com Nigeria

Neuraxis secures $5 million in preferred stock sale - Investing.com

Neuronetics Grants Inducement Awards to New Employees - MSN

NeurAxis Stock Surges After Strong Q3 Earnings And Expanded Coverage - Barchart

Neuraxis Inc. (NRXS) Quarterly 10-Q Report - Quartz

NeurAxis reports 40% increase in revenues in Q3 2024 - Medical Buyer

NeurAxis Reports Strong Revenue Growth in Q3 2024 - TipRanks

NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues - GlobeNewswire

NeurAxis Q3 Revenue Surges 40%, Expands Coverage to 35M Lives Amid FDA Milestone | NRXS Stock News - StockTitan

NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market - Building Indiana

NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024 - GlobeNewswire

Finanzdaten der Neuraxis Inc-Aktie (NRXS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NRXS